CD34 and breast cancer: Lastly, the antitumor activity of DuoBody-CD3x5T4 was studied in CD34+ hematopoietic stem cell (HSC)–humanized NSG mice (NSG-human immune system [HIS] mice) that were SC implanted with MDA-MB-231 breast cancer cells (Fig 5F).